Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

医学 帕妥珠单抗 曲妥珠单抗 蒽环类 内科学 乳腺癌 化疗 肿瘤科 癌症
作者
Andreas Schneeweiß,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,Maeve Waldron-Lynch,Jennifer Eng‐Wong,S Kirk,Javier Cortés
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:89: 27-35 被引量:231
标识
DOI:10.1016/j.ejca.2017.10.021
摘要

Background We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. Methods Descriptive efficacy analyses were conducted in patients randomised to group A (cycles 1–6: trastuzumab [8 mg/kg loading dose and 6 mg/kg maintenance] plus pertuzumab [840 mg loading dose and 420 mg maintenance], plus 5-fluorouracil, epirubicin and cyclophosphamide [FEC] [cycles 1–3; 500 mg/m2 5-fluorouracil/100 mg/m2 epirubicin/600 mg/m2 cyclophosphamide] then docetaxel [cycles 4–6; 75 mg/m2, escalated to 100 mg/m2 if well tolerated]), B (cycles 1–3: FEC, cycles 4–6: trastuzumab plus pertuzumab plus docetaxel as mentioned previously) or C (cycles 1–6: trastuzumab plus pertuzumab plus docetaxel [75 mg/m2, without dose escalation], and carboplatin [AUC 6]), five years after randomisation of the last patient. This study is registered with ClinicalTrials.gov, number NCT00976989. Results Three-year Kaplan–Meier survival estimates for disease-free survival (DFS) were 87% (95% confidence interval: 79–95), 88% (80–96) and 90% (82–97) in groups A–C, respectively. Progression-free survival (PFS) rates were 89% (81–96), 89% (81–96) and 87% (80–95). DFS hazard ratio for total pathological complete response (tpCR) versus no tpCR was 0.27 (0.11–0.64). During post-treatment follow-up, 2/72 (2.8%), 3/75 (4.0%) and 4/76 (5.4%) patients in groups A–C had any-grade left ventricular systolic dysfunction; eight (11.1%), 12 (16.0%) and nine (11.8%) patients experienced left ventricular ejection fraction declines ≥10% from baseline to <50%. Conclusions Long-term DFS and PFS were similar between groups. Patients who achieved tpCR had improved DFS. No new safety signals were identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
超帅听枫发布了新的文献求助10
1秒前
3秒前
3秒前
fish1116发布了新的文献求助100
3秒前
3秒前
bbbbb沫完成签到,获得积分20
3秒前
峥2发布了新的文献求助10
3秒前
wzy完成签到,获得积分10
3秒前
xxxllllll发布了新的文献求助10
4秒前
干净映天完成签到 ,获得积分10
4秒前
LJ_scholar发布了新的文献求助10
5秒前
kuny完成签到,获得积分10
5秒前
勤恳的夏之完成签到,获得积分20
6秒前
wzy发布了新的文献求助10
6秒前
钵钵鸡完成签到 ,获得积分10
6秒前
JING发布了新的文献求助10
6秒前
後zgw完成签到,获得积分10
8秒前
8秒前
9秒前
明朗发布了新的文献求助10
9秒前
meredith0571完成签到,获得积分10
10秒前
10秒前
嗯哼发布了新的文献求助30
10秒前
lucky完成签到 ,获得积分10
10秒前
朴实山彤完成签到,获得积分20
11秒前
11秒前
bkagyin应助ccalvintan采纳,获得10
13秒前
Gpu_broken应助橙子采纳,获得20
13秒前
雪碧发布了新的文献求助10
13秒前
焦糖发布了新的文献求助10
14秒前
14秒前
14秒前
16秒前
16秒前
qqq完成签到,获得积分10
16秒前
jjjdcjcj完成签到,获得积分10
17秒前
打打应助mmol采纳,获得10
17秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021